More importantly, Chst15 siRNA has been tested in a Phase 1 Clinical trial for Crohn’s disease patients with active mucosal lesions, and a Phase I/IIa trial for patients with pancreatic cancer (Tsuchiya et al., 2021), and has a good safety profile (Suzuki et al., 2017). This evidence concerns the gene CHST15 and Crohn disease.